Vertex Pharmaceuticals partners with Lonza on new facility
New England Council member Vertex Pharmaceuticals is partnering with pharmaceutical manufacturing firm, Lonza on the development of a new state-of-the-art facility in Portsmouth, NH.
The development of the new facility, in which Lonza will operate, will be focused on Vertex’s cell therapy solutions for Type 1 Diabetes (T1D). The stem cell-derived treatments, which seek to eliminate the need for auxiliary insulin, have shown clinical proof-of-concept success, and are being refined through testing across multiple clinical trials. This facility will offer a devoted site for the advancement and revision of these groundbreaking efforts, which have the opportunity to drastically reshape how T1D is treated. The facility will stretch over 130,000 square feet and create up to 300 new jobs. The two companies will break ground in Portsmouth on August 30, 2023.
“Establishing this strategic partnership with Lonza, a world-class manufacturing organization, is a critical milestone in this journey and underscores our long-term commitment to patients with T1D,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Vertex’s allogeneic, fully differentiated, insulin-producing islet cells… represent a scientific breakthrough that offers the potential to transform the treatment of T1D.”
The New England Council congratulates Vertex Pharmaceuticals on this partnership and commends its efforts to improve Type 1 Diabetes treatment.
Read more from the NH Business Review.